Literature DB >> 6552258

Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections.

J Klastersky, L Coppens, P van der Auwera, F Meunier-Carpentier.   

Abstract

Infections caused by oxacillin-resistant staphylococci were studied in 27 patients, who received vancomycin therapy as soon as the resistance of the pathogenic staphylococcal strain to oxacillin was documented. Therapy with vancomycin was usually started not later than 48 h after the onset of empiric therapy with oxacillin or cefamandole. In spite of high bactericidal activity in the serum of the patients receiving vancomycin, only 16 (59%) out of 27 patients responded to the treatment. Favourable clinical responses were usually associated with bacteriological cure, but super-infection by Gram-negative bacillary rods was a common complication in this series; it occurred in eight (30%) of the 27 patients studied. The overall death rate was 33% (9/27); death was associated in six patients with persisting staphylococcal infection and in three patients with Gram-negative bacillary superinfection of the bronchopulmonary tract, with or without persistent staphylococcal infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6552258     DOI: 10.1093/jac/11.4.361

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci.

Authors:  M Arditi; R Yogev
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

3.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Severe infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  C T Keane; M T Cafferkey
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  Activity of 18 antimicrobial agents against multi-resistant strains of Staphylococcus aureus isolated from intensive care patients.

Authors:  D Duncker; U Ullmann
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

6.  Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.

Authors:  J I Blenkharn; J H Darrell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections.

Authors:  H Portier; A Kazmierczak; F Lucht; J C Tremeaux; P Chavanet; J M Duez
Journal:  Infection       Date:  1985       Impact factor: 3.553

9.  Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.

Authors:  R Haag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.